ClinicalTrials.gg
Enrolling by invitationNCT05235633Updated Aug 19, 2026

ADLs at the End of Acute Treatment for Childhood Leukemia and Non-Hodgkin Lymphoma

An observational study in Childhood Cancer, sponsored by Technical University of Munich. Enrolling by invitation at 1 site in Germany. Open to participants aged 4 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-08-19.

Sponsored by Technical University of Munich · Observational

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
20
Ages
4 Years to 18 Years
Sex
All
01

Study summary

Reduced activity levels and reduced muscular strength could severely impair the activities of daily living (ADLs) in pediatric leukemia and Non-Hodgkin lymphoma patients. Increased muscle strength is associated with improved accomplishment of ADLs and consequently greatest possible normality, autonomy and mobility. This associated investigation to the study with the ClinicalTrials.gov Identifier NCT03934060 aims at collecting data in a comparison cohort with respect to ADLs in children and adolescents who did not receive a standardized strenght training intervention during the whole course of treatment.

02

Conditions studied

  • Childhood Cancer

Keywords

  • Activities of daily living
  • Leukemia
  • Non-Hodgkin Lymphoma
  • Physical activity
  • Motor performance
03

In context

Neoplasms

10,818 studies on the registry are indexed under Neoplasms; 2,324 are open to participants now.

This study's planned enrollment of 20 is below the median of 200 across 2,638 observational studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Technical University of Munich is the lead sponsor of 320 studies on the registry; 58 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
4 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study polulation will be recruited at the Oncology and Hematology Day Hospital at the Dr. von Hauner Children's Hospital of the University of Munich.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Children and adolescents aged 4-18 years
  • At the end of acute treament for leukemia or non-Hodgkin lymphoma
  • Diagnosed and/or treated at the Dr. von Hauner Children's Hospital, University of Munich
  • as documented by signature

Exclusion criteria

Exclusion Criteria:

  • Medical to perform this unique test battery (e.g., acute bleeding risk, pain, nausea, acute orthopedic impairments)
  • Inability to follow study procedures (e.g., language problems, mental retardation)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
20 participants (estimated)
Patient registry
No

Groups and cohorts

  • Comparison cohort

    Children and adolescents at the end of acute treatment for leukemia and non-Hodgkin lymphoma without any exercise intervention

    Diagnostic Test: Assessment of the accomplishment regarding Activities of Daily Living at the end of acute treatment

Interventions

  • Diagnostic testAssessment of the accomplishment regarding Activities of Daily Living at the end of acute treatment

    Participants perform a test battery to assess the capability to accomplish Activities of Daily Living that includes a standardized and validated questionnaire, a parcour with tasks based on Activities of Daily Living and a motor performance test.

06

What researchers measure

Primary outcomes

  1. Score of the Activities Scale for Kids - performance version

    The ASK - Activities Scale for Kids performance version by NL Young assesses an overall summary score (0-100) of self-reported activities of daily living in children and adolescents. The scale monitors changes associated with therapeutic interventions and the current status of accomplishment of activities of daily living. Higher values represent a better outcome. The ASK contains 30 items in 7 sub-domains (personal care, dressing, other skills, locomotion, play, standing skills and transfer).

    Time frame: During the procedure

Secondary outcomes

  1. Motor Performance

    Motor performance is assessed by the MOON-test (Motor performance test in Pediatiric Oncology), a tool to examine motor performance abilities in children and adolescents during and after cancer treatment. There's no summary score; reference values of healthy children enable comparison of the tested children.

    Time frame: During the procedure

  2. Performance in a Parkour in Activities of Daily Living

    A standardized parkour with tasks imitating activities of daily living is used to objectively verify the ASK score. Points from 0-4 are counted for each task depending on quality of movement (0 = task can not be completed, 1 = task can be completed with help, 2 = task can be completed with several attempts, 3 = task can be completed with only little effort, 4 = task can be completed without any problems or effort). There are no reference values for the parkour, but intra-individual changes are analyzed.

    Time frame: During the procedure

07

Study locations

1 site
  • Kinderklinik München Schwabing, TUM School of Medicine, Department of Paediatrics and Children's Cancer Research Center, Technical University of Munich, Germany
    Munich, 80804, Germany
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05235633
Responsible party
Sabine Kesting (Principal Investigator, Technical University of Munich) — Principal investigator
First posted
Feb 11, 2022
Start date
Apr 19, 2022
Primary completion
Jul 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Aug 19, 2026

Study contacts

Sabine Kesting
principal investigator · Kinderklinik München Schwabing TUM School of Medicine, Department of Pediatrics and Children's Cancer Research Center, Technical University of Munich

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion